All In Biotech

Drug Trial Radar · NCT02562235

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

24

Actual

Start

Oct 29, 2015

Primary completion

Mar 7, 2020

Study completion May 15, 2028

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Sep 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study design consisted of a main study part followed by an optional long-term extension part. The main treatment period consisted of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.

Conditions

  • Hypertension, Pulmonary

Interventions

  • Riociguat (Adempas, BAY63-2521)Drug

    For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Treatment-emergent Adverse EventsTime frame: From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days.
  2. Change in Heart Rate From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  3. Change in Blood Pressure From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  4. Change in Respiratory Rate From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  5. Number of Subjects With Transitions From Baseline in Bone Age Compared to Chronological AgeTime frame: Baseline and Week 24 (plus/minus 5 days)
  6. Change in Hematology Parameters (Platelets) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  7. Change in Hematology Parameters (Lymphocytes/Leucocytes Ratio) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  8. Change in Hematology Parameter (Neutrophils/Leucocytes Ratio) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  9. Change in Clinical Chemistry (Alanine Aminotransferase) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  10. Change in Clinical Chemistry (Aspartate Aminotransferase) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  11. Change in Clinical Chemistry (Sodium) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  12. Change in Clinical Chemistry (Blood Urea Nitrogen) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  13. Change in Clinical Chemistry (eGFR) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  14. Change in Clinical Chemistry (Urea) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  15. Change in Clinical Chemistry (Gamma Glutamyl Transferase) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
  16. Plasma Concentration of Riociguat at Week 0Time frame: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
  17. Plasma Concentration of Riociguat at Week 4Time frame: Week 4 (pre-dose)
  18. Plasma Concentration of Riociguat at Week 8Time frame: Week 8 (pre-dose)
  19. Plasma Concentration of BAY60-4552 at Week 0Time frame: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
  20. Plasma Concentration of BAY60-4552 at Week 4Time frame: Week 4 (pre-dose)
  21. Plasma Concentration of BAY60-4552 at Week 8Time frame: Week 8 (pre-dose)

Locations

16 sites in 9 countries. Site status is shown where the registry gives one.

  • Clínica Imbanaco S.A.S

    Cali, Valle del Cauca Department, Colombia

  • Universitätsklinikum Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany

  • Deutsches Herzzentrum der Charité (DHZC)

    Berlin, State of Berlin, Germany

  • Gottsegen Gyorgy Orszagos Kardiovaszkularis Intezet

    Budapest, Budapest, Hungary

  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

    Szeged, Csongrád-Csanád, Hungary

  • Azienda Ospedale-Università di Padova - UOC Cardiologia Pediatrica

    Padova, Veneto, Italy

  • Aichi Children's Health and Medical Center

    Ōbu, Aichi-ken, Japan

  • The University of Osaka Hospital

    Suita, Osaka, Japan

  • National Cerebral and Cardiovascular Center

    Suita, Osaka, Japan

  • Keio University Hospital

    Shinjuku-ku, Tokyo, Japan

  • Instituto Nacional de Cardiología "Ignacio Chávez"

    México D.F., Mexico City, Mexico

  • Operadora de Hospitales Angeles S. A. de C. V.

    Huixquilucan, State of Mexico, Mexico

  • Wojewodzki Szpital Specjalistyczny - Wroclaw

    Wroclaw, Poland

  • Veterans General Hospital

    Kaohsiung City, Kaohsiung, Taiwan

  • Hacettepe Universitesi Tip Fakultesi

    Ankara, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.